Skip to content

A Gender-Specific Study on the Efficacy of Modified Electroconvulsive Therapy in Depressed Patients with Suicidal Symptoms

A Gender-Specific Study on the Efficacy of Modified Electroconvulsive Therapy in Depressed Patients with Suicidal Symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112537
Enrollment
Unknown
Registered
2025-11-17
Start date
2025-11-24
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

MECT combined with conventional antidepressant treatment group:None
Conventional antidepressant treatment group:None

Sponsors

Beijing Anding Medical Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.MECT Combined with Medication Group - Inclusion Criteria: (1)Aged 16–45 years; (2)Meets the diagnostic criteria for a depressive episode according to DSM-5; (3)Scores >0 on the Scale for Suicide Ideation (SSI); (4)Has not received physical therapies such as MECT or transcranial magnetic stimulation within the past two weeks; (5)MECT is clinically recommended, and the patient or their guardian has provided written informed consent for MECT; (6)Able to cooperate with completing MRI examinations and cognitive function assessments; (7)Written informed consent is obtained from the patient or their family members. 2.Antidepressant Medication Group - Inclusion Criteria: (1)Aged 16–45 years; (2)Meets the diagnostic criteria for a depressive episode according to DSM-5; (3)Scores >0 on the Scale for Suicide Ideation (SSI); (4)Has not received physical therapies such as MECT or transcranial magnetic stimulation within the past two weeks; (5)Able to cooperate with completing MRI examinations and cognitive function assessments; (6)Written informed consent is obtained from the patient or their family members.

Exclusion criteria

Exclusion criteria: 1.MECT Combined with Medication Group - Exclusion Criteria: (1)History of cranial diseases, brain injury, epileptic seizures, or other neurological disorders; (2)History of severe systemic diseases, including cardiovascular, respiratory, or immune system diseases; (3)History of alcohol or opioid abuse; (4)Allergy to both propofol and etomidate, or allergy to succinylcholine; other contraindications to MECT; (5)Pregnancy, lactation, or other somatic conditions affecting the secretion of estradiol, testosterone, or cortisol; (6)Contraindications to MRI scanning, such as implanted cardiac pacemakers or arterial clips. 2.Antidepressant Medication Group - Exclusion Criteria: (1)History of cranial diseases, brain injury, epileptic seizures, or other neurological disorders; (2)History of severe systemic diseases, including cardiovascular, respiratory, or immune system diseases; (3)History of alcohol or opioid abuse; (4)Pregnancy, lactation, or other somatic conditions affecting the secretion of estradiol, testosterone, or cortisol; (5)Contraindications to MRI scanning, such as implanted cardiac pacemakers or arterial clips.

Design outcomes

Primary

MeasureTime frame
Suicide remission rate;

Secondary

MeasureTime frame
Improvement of depressive symptoms;

Countries

China

Contacts

Public ContactYanping Ren

Beijing Anding Medical Hospital, Capital Medical University

renyanping@sina.com+86 132 8040 8866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026